Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > New Hope for Patients Suffering from Degenerative, Inflammatory Eye Diseases

TheraKine and Capsulution Start Joint Development

New Hope for Patients Suffering from Degenerative, Inflammatory Eye Diseases

Berlin, Germany | Posted on October 1st, 2007

Capsulution NanoScience AG, a Berlin-based company, and TheraKine Ltd., an Irish company with significant operations in the United States, are establishing a joint project for the treatment of serious eye diseases. Their aim is to develop an innovative drug-delivery system for ophthalmic applications which will enable local sustained release of one or multiple anti-inflammatory and anti-proliferative biologic and small molecule compounds. This will allow the therapy of difficult to treat eye diseases such as uveitis, diabetic retinopathy and age-related macular degeneration (AMD).

The current treatment possibilities for inflammation of the eye are more than unsatisfactory. Steroids and immunosuppressants have many severe side effects and limited efficacy. Biologic compounds need regularly repeated intravenously or intravitreal injections at relatively high doses. When administered systemically, only traces of the compound reach the interior of the eye, but cause undesirable side effects due to high levels of the compound in other parts of the body. Intravitreal injections offer a solution to this; but currently these still require repeated injections and are limited to a small number of anti-VEGF drugs or long acting steroids. Only a small fraction of patients can be treated with current technology, and there are significant side effects such as internal bleeding, cataracts, retinal damage, increase of pressure inside the eye, and infection.

With the aid of Capsulution's formulation technology, TheraKine will bring an innovative drug-delivery system to the market. "We selected Capsulution because they have the right IP, skilled staff, and an entrepreneurial spirit.", explains TheraKine's CEO Scott Hampton. The collaboration with the internationally-renowned developer of nanocomplexes offers a promising advance towards the formulation of very easily degradable, water-soluble biologic compounds in combination with water-insoluble anti-inflammatory compounds or small molecules. According to Capsulution's Project CSO, Dr. Voigt: "For this application, controlled and sustained release of a pre-defined amount of compound is required." The compound depot in the biodegradable implant should, if possible, only be injected into the eye once.

Mr. Hampton declares: "TheraKine's mission is the creation of therapeutic system to improve vision and prevent blindness". He emphasizes the urgency of the situation: "Effective and safe treatments are desperately needed by millions of people who are currently suffering progressive vision loss due to chronic inflammatory and degenerative eye diseases. Our targeted local delivery will offer safety, effectiveness, and affordable treatment costs."


About Capsulution NanoScience AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.

About TheraKine:
TheraKine was founded in 2004 when a widely respected physician
discovered better treatments for children who were rapidly losing
their eyesight due to chronic inflammatory eye disease. Frustrated by
the limitations of existing systemic delivery systems, the TheraKine
team soon decided that a local, targeted approach to delivery would
produce a much more effective and efficient outcome for the patient.
This work continues, with exciting results in feasibility trials.
TheraKine estimates that the first human clinical trials will start
in the fourth quarter of 2009.

For more information, please click here

Herr Dipl.-Kfm. Alexander Herrmann

Telefon: +49 (30) 6706919-129
Fax: +49 (30) 6706919-101
Zuständigkeitsbereich: Chief Financial Officer (CFO)

Herr Jerry Seelig
TheraKine Ltd.

Telefon: +1 (678) 648-4037
Fax: +1 (678) 623-9550
Zuständigkeitsbereich: Senior Business Development

Copyright © Capsulution NanoScience AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Electron tomography with 3,487 images in 3.5 seconds: High-speed electron tomography sets new standards for 3-D images of the nanoworld October 6th, 2015

Brightness-equalized quantum dots improve biological imaging October 5th, 2015

Sniffing out cancer with improved 'electronic nose' sensors October 2nd, 2015

Hopes of improved brain implants October 1st, 2015


Discovery about new battery overturns decades of false assumptions October 7th, 2015

Modification of Nanofiltration Membranes in Water Purification Process October 7th, 2015

Nanoscale photodetector shows promise to improve the capacity of photonic circuits: Researchers at the University of Rochester have fabricated a device in which light can induce a current using a silver nanowire -- an important step toward harnessing light to speed up the next ge October 6th, 2015

Big range of behaviors for tiny graphene pores: Like biological channels, graphene pores are selective for certain types of ions October 6th, 2015

Alliances/Trade associations/Partnerships/Distributorships

SUNY Poly Announces Joint Development Agreement with INFICON to Establish Cutting Edge R&D Partnership Supporting New York State’s Rapidly Expanding Nanoelectronics Industry September 23rd, 2015

Pushing the limits of lensless imaging: At the Frontiers in Optics conference researchers will describe a custom-built ultrafast laser that could help image everything from semiconductor chips to cells in real time September 21st, 2015

Nanotech expertise earns Virginia Tech a spot in National Science Foundation network: New center's focus will be on earth, environmental nanotechnology September 16th, 2015

Graphene Enhanced ARALDITE Resin Composite Materials September 14th, 2015

Research partnerships

Molecular nanoribbons as electronic highways October 6th, 2015

Observing the unobservable: Researchers measure electron orbitals of molecules in 3-D October 6th, 2015

Research improves efficiency from larger perovskite solar cells October 6th, 2015

ORNL researchers find 'greener' way to assemble materials for solar applications October 5th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic